中國生物科技服務(08037.HK)與平安健康訂立戰略合作框架協議
格隆匯7月11日丨中國生物科技服務(08037.HK)發佈公吿,於2022年7月11日,公司與平安健康互聯網股份有限公司上海分公司訂立戰略合作框架協議,據此,由框架協議簽訂日期起至2025年7月10日止,訂約方同意就健康管理產品和服務的銷售進行合作。
建議合作的範圍包括下列各項:集團可利用醫療資源優勢,為平安健康用户提供硼中子俘獲治療板塊相關服務;利用訂約方在各自領域的優勢,建議合作可以讓創新藥物觸及更多的用户;集團旗下香港的檢測中心可為平安健康用户提供(i)檢測服務及雙語版本檢測報吿;(ii)癌症檢測服務;及(iii)本地專家會診預約協助服務。集團可為平安健康用户提供(i)香港及日本的就醫協助;(ii)遠程問診服務安排;(iii)二次診斷服務安排;(iv)高端精密體檢預約服務;(v)手術後照護服務;及(vi)定期跟進服務和檢測服務。
據悉,平安健康互聯網股份有限公司是一家在中國註冊成立的公司,主要從事開發及運營移動平台“平安健康平台”。平安健康互聯網股份有限公司是平安健康醫療科技有限公司(股份代號:1833)根據合約安排控制的經營實體。截至2021年年末,平安健康平台累計註冊用户達4.2億;累計諮詢量也保持行業領先地位,達12.7億人次。與此同時,獲客渠道的聚焦帶來全年累計付費用户數的快速增長,超過3,800萬。
集團深耕香港醫學檢測及健康管理服務市場,並正在積極佈局硼中子俘獲治療、嵌合抗原受體T細胞療法、疫苗等精準治療領域。董事會認為,訂立框架協議可以為集團帶來更多商機,並使集團能夠利用資源豐富的平安健康平台擴大其產品和服務的地域和客户覆蓋範圍。建議合作將促進集團的企業發展,符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.